Key points are not available for this paper at this time.
Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies. Chimeric antigen receptor–modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission in patients with refractory disease.
Building similarity graph...
Analyzing shared references across papers
Loading...
Shannon L. Maude
Noelle V. Frey
Pamela A. Shaw
New England Journal of Medicine
University of Pennsylvania
Children's Hospital of Philadelphia
Building similarity graph...
Analyzing shared references across papers
Loading...
Maude et al. (Wed,) studied this question.
www.synapsesocial.com/papers/68f648ee33dca03d982ea4a4 — DOI: https://doi.org/10.1056/nejmoa1407222